Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1.
Cell Adhesion
/ genetics
Cell Movement
/ genetics
Endothelial Cells
/ metabolism
Humans
Neovascularization, Pathologic
/ genetics
Neovascularization, Physiologic
/ genetics
Neurons
/ metabolism
Neuropilin-1
/ genetics
Phosphorylation
/ genetics
Protein Binding
/ genetics
Signal Transduction
/ genetics
Vascular Endothelial Growth Factor A
/ genetics
Vascular Endothelial Growth Factor Receptor-1
/ genetics
Vascular Endothelial Growth Factor Receptor-2
/ genetics
angiogenesis
neuropilin-1
peptides
vascular endothelial growth factor receptor 1
α5β1 integrin
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
27
05
2021
received:
11
11
2019
accepted:
12
07
2021
pubmed:
13
7
2021
medline:
26
2
2022
entrez:
12
7
2021
Statut:
ppublish
Résumé
Neuropilin-1 (NRP-1) is a semaphorin receptor involved in neuron guidance, and a co-receptor for selected isoforms of the vascular endothelial growth factor (VEGF) family. NRP-1 binding to several VEGF-A isoforms promotes growth factor interaction with VEGF receptor (VEGFR)-2, increasing receptor phosphorylation. Additionally, NRP-1 directly interacts with VEGFR-1, but this interaction competes with NRP-1 binding to VEGF-A165 and does not enhance VEGFR-1 activation. In this work, we investigated in detail the role of NRP-1 interaction with the soluble isoform of VEGFR-1 (sVEGFR-1) in angiogenesis. sVEGFR-1 acts both as a decoy receptor for VEGFs and as an extracellular matrix protein directly binding to α5β1 integrin on endothelial cells. By combining cell adhesion assays and surface plasmon resonance experiments on purified proteins, we found that sVEGFR-1/NRP-1 interaction is required both for α5β1 integrin binding to sVEGFR-1 and for endothelial cell adhesion to a sVEGFR-1-containing matrix. We also found that a previously reported anti-angiogenic peptide (Flt
Identifiants
pubmed: 34252269
doi: 10.1111/febs.16119
pmc: PMC9290910
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Neuropilin-1
144713-63-3
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-198Informations de copyright
© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Neurosci. 1999 Aug 1;19(15):6519-27
pubmed: 10414980
Electrophoresis. 1993 Oct;14(10):1023-31
pubmed: 8125050
Drug Discov Today. 2013 May;18(9-10):447-55
pubmed: 23228652
Blood. 2008 Apr 1;111(7):3479-88
pubmed: 18184864
Cell. 1999 Oct 1;99(1):59-69
pubmed: 10520994
Circ Res. 2008 Jun 20;102(12):1566-74
pubmed: 18515749
PLoS One. 2014 Jul 07;9(7):e101931
pubmed: 24999732
Int J Mol Sci. 2018 Apr 23;19(4):
pubmed: 29690653
Arthritis Rheum. 2010 Jan;62(1):179-90
pubmed: 20039409
Br J Cancer. 2010 Feb 2;102(3):541-52
pubmed: 20087344
Exp Ther Med. 2013 Jan;5(1):150-154
pubmed: 23251257
Int J Oncol. 2016 Apr;48(4):1581-9
pubmed: 26846845
Cancer Biol Ther. 2007 Aug;6(8):1173-80
pubmed: 17726369
Cancer Lett. 2016 Apr 1;373(1):1-11
pubmed: 26805761
J Biol Chem. 1998 Aug 28;273(35):22272-8
pubmed: 9712843
Cell. 1998 Mar 20;92(6):735-45
pubmed: 9529250
Adv Exp Med Biol. 2002;515:81-90
pubmed: 12613545
J Cell Sci. 2017 Apr 15;130(8):1365-1378
pubmed: 28254885
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Br J Cancer. 2018 Jun;118(12):1596-1608
pubmed: 29795310
Electrophoresis. 1997 Dec;18(15):2714-23
pubmed: 9504803
Front Oncol. 2015 Jun 03;5:125
pubmed: 26090340
Cancer Cell. 2007 Jan;11(1):53-67
pubmed: 17222790
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Biochem Biophys Res Commun. 1996 Sep 13;226(2):324-8
pubmed: 8806634
Cell. 1997 Aug 22;90(4):739-51
pubmed: 9288753
Cell. 1997 Aug 22;90(4):753-62
pubmed: 9288754
FASEB J. 2014 Feb;28(2):692-704
pubmed: 24174428
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
FEBS Lett. 2000 Mar 3;469(1):14-8
pubmed: 10708747
Oncogene. 2016 Aug 18;35(33):4379-87
pubmed: 26804163
Blood. 2005 Mar 1;105(5):1992-9
pubmed: 15522955
Cancer Immunol Immunother. 2014 Feb;63(2):81-99
pubmed: 24263240
J Biol Chem. 2000 Jun 16;275(24):18040-5
pubmed: 10748121
Structure. 2016 Nov 1;24(11):2008-2015
pubmed: 27720589
Prog Hemost Thromb. 1976;3:1-28
pubmed: 181786
J Cell Sci. 2003 Sep 1;116(Pt 17):3479-89
pubmed: 12865438
Life Sci. 2006 Nov 17;79(25):2370-81
pubmed: 16959272
Dev Biol. 1995 Jul;170(1):207-22
pubmed: 7601310
J Biol Chem. 1999 Jun 25;274(26):18421-7
pubmed: 10373449
J Cell Biol. 2000 Mar 20;148(6):1283-93
pubmed: 10725340
Cancer Res. 2013 Jul 15;73(14):4579-4590
pubmed: 23689123
Development. 1995 Dec;121(12):4309-18
pubmed: 8575331
Development. 1999 Nov;126(21):4895-902
pubmed: 10518505
Cell. 1997 Nov 28;91(5):695-704
pubmed: 9393862
Eur J Cancer. 2008 Sep;44(13):1914-21
pubmed: 18682321
J Biol Chem. 2009 Dec 4;284(49):33966-81
pubmed: 19837659
J Biol Chem. 2002 May 17;277(20):18069-76
pubmed: 11886873
Am J Pathol. 2006 Oct;169(4):1167-82
pubmed: 17003476
J Biol Chem. 2000 Sep 1;275(35):26690-5
pubmed: 10842181
Sci Rep. 2015 Nov 18;5:16828
pubmed: 26577048
Front Cell Dev Biol. 2020 May 26;8:395
pubmed: 32528960
PLoS Biol. 2009 Jan 27;7(1):e25
pubmed: 19175293
Cancer Res. 2012 Aug 15;72(16):4047-59
pubmed: 22738912
FEBS Lett. 2001 Apr 13;494(3):150-6
pubmed: 11311231